Biotech firm Pulmocide has received £17m ($27.84m) in series A backing as the Imperial College London (ICL) spin-out heads to the institution’s BioIncubator. ICL’s tech transfer unit Imperial Innovations invested £4.25m in the round, and was joined by a venture consortium of SV Life Sciences, Fidelity Biosciences, and pharmaceutical giant Johnson & Johnson’s corporate venturing…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
